Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, N.Y., United States

Survival: 6.1 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Gleevec
Country: United States
City/State/Province: New York, N.Y.
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 3/2005

Patients: This Phase II study involved 16 women with metastatic breast cancer. The median age was 55 years. All but one received chemotherapy before the study, and all had at least one metastatic site.

Treatment: The treatment consisted of imatinib an inhibitor of a number of tyrosine kinase enzymes.

Toxicity: Grade 3-4 toxicities included lymphopenia.

Results: The median overall survival was 6.08 months. The authors concluded that they did not see a significant therapeutic benefit as none of the patients remained on the study after 3 months.

Support: Novartis Pharmaceuticals financially supported this study. Novartis manufactures imanitib.

Correspondence: Clifford A. Hudis, MD

E-mail to a Friend Email Physician More Information